ROSEN, LEADING INVESTOR COUNSEL, Encourages Erasca, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ERAS

Rosen Law Firm is reminding investors who purchased Erasca, Inc. common stock between January 14, 2025 and April 26, 2026 of the August 10, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that Erasca and its executives made false and misleading statements about its lead oncology drug candidate ERAS-0015, including improper comparisons to a competing drug and undisclosed patent disputes.